Lakshmi A Devi Selected Research

Opiate Alkaloids

1/2020	Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions.
4/2012	Opioid receptor heteromers in analgesia.
3/2012	Functional relevance of μ-δ opioid receptor heteromerization: a role in novel signaling and implications for the treatment of addiction disorders: from a symposium on new concepts in mu-opioid pharmacology.
12/2011	Mice deficient in endothelin-converting enzyme-2 exhibit abnormal responses to morphine and altered peptide levels in the spinal cord.
1/2011	Chronic morphine alters the presynaptic protein profile: identification of novel molecular targets using proteomics and network analysis.
3/2010	Modulation of opiate-related signaling molecules in morphine-dependent conditioned behavior: conditioned place preference to morphine induces CREB phosphorylation.
2/2010	Cannabinoid-opioid interactions during neuropathic pain and analgesia.
11/2007	An emerging role for the delta opioid receptor in the regulation of mu opioid receptor function.
8/2007	Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers.
4/2004	A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lakshmi A Devi Research Topics

Disease

23	Pain (Aches) 01/2022 - 03/2006
9	Chronic Pain 01/2022 - 04/2004
9	Neuralgia (Stump Neuralgia) 01/2022 - 02/2010
7	Body Weight (Weight, Body) 01/2019 - 03/2004
6	Hyperalgesia 01/2022 - 10/2011
6	Opioid-Related Disorders (Opiate Addiction) 01/2020 - 04/2008
3	Substance-Related Disorders (Drug Abuse) 01/2019 - 03/2006
2	Obesity 01/2022 - 12/2002
2	Respiratory Insufficiency (Respiratory Failure) 11/2020 - 01/2020
2	Nausea 01/2018 - 01/2012
1	Diabetic Neuropathies (Diabetic Neuropathy) 01/2022
1	Congenital Pain Insensitivity 01/2022
1	Hereditary Sensory and Autonomic Neuropathies (HSAN) 01/2022
1	Diabetes Mellitus 01/2022
1	Autonomic Nervous System Diseases (Dysautonomia) 12/2020
1	Hypersensitivity (Allergy) 01/2020
1	Fibromyalgia (Fibrositis) 10/2019
1	Peripheral Nervous System Diseases (PNS Diseases) 08/2019
1	Sleep Wake Disorders 01/2018
1	Mental Disorders (Mental Disorder) 12/2017
1	Mood Disorders (Mood Disorder) 12/2017
1	Cocaine-Related Disorders (Cocaine Addiction) 05/2016
1	Visceral Pain 05/2016
1	Neoplasms (Cancer) 02/2016
1	Triple Negative Breast Neoplasms 02/2016
1	Pathologic Processes 01/2016
1	Diarrhea 12/2014
1	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 12/2014
1	Acute Pain 03/2014
1	Fatty Liver 03/2014
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2013
1	Schizophrenia (Dementia Praecox) 01/2013

Drug/Important Bio-Agent (IBA)

15	Morphine (MS Contin)FDA LinkGeneric 01/2020 - 04/2004
11	Opioid Receptors (Opioid Receptor)IBA 01/2022 - 03/2006
10	Opiate AlkaloidsIBA 01/2020 - 04/2004
9	Opioid Analgesics (Opioids)IBA 01/2022 - 02/2010
8	Peptides (Polypeptides)IBA 01/2022 - 12/2002
7	Analgesics (Analgesic Drugs)IBA 01/2022 - 04/2004
6	Proteins (Proteins, Gene)FDA Link 10/2019 - 08/2006
5	NeuropeptidesIBA 01/2022 - 03/2004
5	LigandsIBA 08/2019 - 08/2006
4	Pharmaceutical PreparationsIBA 01/2022 - 07/2007
3	CannabinoidsIBA 01/2022 - 02/2010
3	hemopressinIBA 01/2022 - 12/2007
3	Fentanyl (Sublimaze)FDA LinkGeneric 01/2020 - 04/2012
3	delta Opioid Receptors (delta Opioid Receptor)IBA 08/2019 - 04/2004
3	Neuropeptide Receptors (Neuropeptide Receptor)IBA 01/2019 - 12/2017
3	Cannabinoid Receptors (Cannabinoid Receptor)IBA 06/2014 - 01/2012
2	EnzymesIBA 01/2022 - 12/2002
2	Opioid Peptides (Opioid Peptide)IBA 01/2020 - 12/2002
2	mu Opioid Receptors (mu Opioid Receptor)IBA 10/2019 - 10/2008
2	4- (alpha- (4- allyl- 2,5- dimethyl- 1- piperazinyl)- 3- methoxybenzyl)- N,N- diethylbenzamideIBA 08/2019 - 02/2012
2	Glucose (Dextrose)FDA LinkGeneric 11/2017 - 06/2010
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 02/2010 - 10/2008
1	EndocannabinoidsIBA 01/2022
1	3-(2-carboxyindol-3-yl)propionic acidIBA 01/2022
1	Streptozocin (Streptozotocin)FDA Link 01/2022
1	Cholinergic Agents (Cholinergics)IBA 12/2020
1	Muscarinic M3 ReceptorIBA 12/2020
1	AutoantibodiesIBA 12/2020
1	Cholinergic ReceptorsIBA 12/2020
1	Synthetic DrugsIBA 01/2020
1	CYM51010IBA 01/2020
1	Biological ProductsIBA 01/2020
1	ORALIT (ORS)IBA 01/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 08/2019
1	HU 211 (HU 210)IBA 08/2019
1	Transient Receptor Potential ChannelsIBA 10/2018
1	CholesterolIBA 11/2017
1	Triglycerides (Triacylglycerol)IBA 11/2017
1	Histamine (Histamine Dihydrochloride)FDA Link 05/2016
1	Estrogen ReceptorsIBA 02/2016
1	Protein Kinase CIBA 02/2016
1	MS0015203IBA 01/2016
1	UbiquitinIBA 10/2015
1	eluxadolineIBA 12/2014
1	Castor Oil (Oil, Castor)IBA 12/2014
1	Loperamide (Imodium)FDA LinkGeneric 12/2014
1	Adrenergic Receptors (Adrenergic Receptor)IBA 06/2014
1	Yohimbine (Yocon)IBA 06/2014
1	Methysergide (Sansert)FDA Link 06/2014
1	CannabidiolIBA 03/2014
1	mitragynineIBA 03/2014
1	naltrindoleIBA 03/2014
1	7-hydroxymitragynineIBA 03/2014
1	methyl 2- (3- ethyl- 9- fluoro- 7a- hydroxy- 8- methoxy- 1,2,3,4,6,7,7a,12,12a,12b- decahydroindolo(2,3- a)quinolizin- 2- yl)- 3- methoxyacrylateIBA 03/2014
1	Indole AlkaloidsIBA 03/2014
1	Neuropeptide YIBA 10/2013
1	LeptinIBA 10/2013
1	GhrelinIBA 10/2013
1	EndorphinsIBA 07/2013
1	Ethanol (Ethyl Alcohol)IBA 01/2013
1	Adenylyl Cyclases (Adenylyl Cyclase)IBA 02/2012
1	D-Penicillamine (2,5)- EnkephalinIBA 02/2012

Therapy/Procedure

7	Therapeutics 11/2020 - 04/2004
5	Analgesia 01/2022 - 02/2010
2	Drug Therapy (Chemotherapy) 08/2019 - 02/2010
2	Oral Administration 11/2017 - 06/2014
1	Glycemic Control 01/2022
1	Subcutaneous Injections 01/2020